Journal
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY
Volume 310, Issue 8, Pages F689-F696Publisher
AMER PHYSIOLOGICAL SOC
DOI: 10.1152/ajprenal.00502.2015
Keywords
nephrin; megalin; podocyte; proximal tubule; sodium-glucose cotransporter
Categories
Funding
- National Institutes of Health [HL49277, HL70523, HL71266, DK34987]
- Career Development Award from the Juvenile Diabetes Research Foundation [2006-102]
Ask authors/readers for more resources
Transforming growth factor-beta 1 (TGF-beta 1) is established to be involved in the pathogenesis of diabetic nephropathy. The diabetic milieu enhances oxidative stress and induces the expression of TGF-beta 1. TGF-beta 1 promotes cell hypertrophy and extracellular matrix accumulation in the mesangium, which decreases glomerular filtration rate and leads to chronic renal failure. Recently, TGF-beta 1 has been demonstrated to regulate urinary albumin excretion by both increasing glomerular permeability and decreasing reabsorption in the proximal tubules. TGF-beta 1 also increases urinary excretion of water, electrolytes and glucose by suppressing tubular reabsorption in both normal and diabetic conditions. Although TGF-beta 1 exerts hypertrophic and fibrogenic effects in diabetic nephropathy, whether suppression of the function of TGF-beta 1 can be an option to prevent or treat the complication is still controversial. This is partly because adrenal production of mineralocorticoids could be augmented by the suppression of TGF-beta 1. However, differentiating the molecular mechanisms for glomerulosclerosis from those for the suppression of the effects of mineralocorticoids by TGF-beta 1 may assist in developing novel therapeutic strategies for diabetic nephropathy. In this review, we discuss recent findings on the role of TGF-beta 1 in diabetic nephropathy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available